Strategic Business Partnership with Novo
Novo is a global healthcare company driving change for lasting health, with more than a century of scientific innovation spanning diabetes and obesity care. The company has a longstanding relationship with the University of Oxford, a global leader in metabolism research. In 2017, the Novo Nordisk Research Centre Oxford (NN R&D UK) was established as part of a strategic alliance between the two organisations.
About the Oxford–Novo partnership
The strategic partnership between Novo and the University of Oxford brings together complementary scientific expertise and resources to advance innovative research at pace and translate cardiometabolic science into potential new medicines. The partnership has evolved from its original focus on diabetes research and talent development into a broader challenge-led co-creation model, fostering closer ties between Oxford researchers and Novo scientists to deliver greater impact for patients.
Projects have been jointly developed and co-funded through a dedicated governance structure comprising a Joint Strategic Committee and a Joint Scientific Advisory Panel. NN R&D UK also contributes to training the next generation of diabetes research scientists by co-sponsoring students.
Notably, the partnership has seen Novo establish an on-site presence at the University of Oxford through the Novo Nordisk Research Centre Oxford (NN R&D UK). NN R&D UK researchers are based in state-of-the-art laboratories in the Innovation Building on the Old Road Campus, which officially opened in September 2018.
As one of Novo’s global R&D hubs, NN R&D UK brings together research and development capabilities in Oxford, London and across the UK, spanning target discovery, computational biology, AI and digital innovation, and clinical development. The hub combines scientific expertise and advanced technologies to translate human biology and data into new therapeutic opportunities.
Partnership Activities
- Novo–Oxford Fellowship Programme
- Sponsored research
- Clinical trials
- DPhil studentships
- Visiting professorships
Therapeutic Focus areas
- Obesity
- Diabetes
- Cardiovascular diseases
- Liver diseases
- Rare blood and endocrine disorders
Partnership Manager
Related News
-
Oxford researchers join Novo, Gates, and Wellcome to tackle antimicrobial resistance
Oxford researchers from the Nuffield Department of Medicine are part of a major new international initiative with the Novo Nordisk Foundation, Wellcome and the Gates Foundation to accelerate the discovery of urgently needed antibiotics. The Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) brings together global expertise to tackle drug-resistant Gram-negative infections, one of the most serious threats to global health.